List of Sympazan drug patents

Sympazan is owned by Aquestive.

Sympazan contains Clobazam.

Sympazan has a total of 2 drug patents out of which 0 drug patents have expired.

Sympazan was authorised for market use on 01 November, 2018.

Sympazan is available in film;oral dosage forms.

The generics of Sympazan are possible to be released after 03 April, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 AQUESTIVE Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(1 year, 19 days from now)

US8603514 AQUESTIVE Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

Sympazan is owned by Otter Pharms.

Sympazan contains Clobazam.

Sympazan has a total of 1 drug patent out of which 0 drug patents have expired.

Sympazan was authorised for market use on 01 November, 2018.

Sympazan is available in film;oral dosage forms.

Sympazan can be used as method of treating seizures.

The generics of Sympazan are possible to be released after 05 September, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541002 OTTER PHARMS NA
Sep, 2039

(16 years from now)

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic